Tofacitinib for the treatment of moderate-to-severe psoriasis (Q38349779)

2 September 2017

1 reference

title

Tofacitinib for the treatment of moderate-to-severe psoriasis (English)

1 reference

2 September 2017

Maria Sole Chimenti

7

0 references

author name string

Andrea Chiricozzi

1

1 reference

2 September 2017

Sara Faleri

2

1 reference

2 September 2017

Rosita Saraceno

3

1 reference

2 September 2017

Luca Bianchi

4

1 reference

2 September 2017

Oreste Buonomo

5

1 reference

2 September 2017

Sergio Chimenti

6

1 reference

2 September 2017

language of work or name

1 reference

10 February 2015

1 reference

Expert Review of Clinical Immunology

2 September 2017

1 reference

2 September 2017

11

1 reference

2 September 2017

4

1 reference

2 September 2017

443-455

1 reference

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

2 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The histopathologic spectrum of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

21 January 2018

Immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Resident and "inflammatory" dendritic cells in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

IL-23 drives pathogenic IL-17-producing CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Consensus guidelines for the management of plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Novel treatments with small molecules in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

New drugs and treatment targets in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

An insight into JAK-STAT signalling in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Targeting signaling pathways with small molecules to treat autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Jakpot! New small molecules in autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Interferon-induced nuclear signalling by Jak protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Jaks and STATs: biological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Series introduction. JAK-STAT signaling in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Cytokine signaling modules in inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Regulation of JAK-STAT signalling in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The many faces of Janus kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

JAK-STAT signaling: from interferons to cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

STATs and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

STAT1 expression and activation is increased in lesional psoriatic skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

TH1/TH2 cell differentiation and molecular signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

IL-17 targeted therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Interleukin-6 as a key player in systemic inflammation and joint destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.1013534

10.1586/1744666X.2015.1013534

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference